Interleukin-6 - Yeda

Drug Profile

Interleukin-6 - Yeda

Alternative Names: IL-6; r-hIL6; Recombinant human interleukin-6; Sigosix®; SJ0031; β2-interferon

Latest Information Update: 05 Dec 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yeda
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Haematological disorders; Haematological malignancies; Preleukaemia; Thrombocytopenia

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Mar 2000 Suspended-I for Cancer in USA (Unknown route)
  • 01 Mar 2000 Suspended-II for Cancer in European Union (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top